GSK3B
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Abemaciclib | 96.5 | 0.56 |
| Defactinib | 96.3 | 0.45 |
| Encorafenib | 91.5 | 0.76 |
| Midostaurin | 78.4 | 0.50 |
| Deucravacitinib | 75.0 | 0.72 |
| Pacritinib | 70.7 | 0.45 |
| Vemurafenib | 59.9 | 0.60 |
| Neratinib | 56.5 | 0.60 |
| Pralsetinib | 49.2 | 0.64 |
| Nintedanib | 45.9 | 0.61 |
| Darovasertib | 36.8 | 0.72 |
| Fostamatinib | 23.7 | 0.61 |
| Dabrafenib | 23.2 | 0.63 |
| Selpercatinib | 22.6 | 0.64 |
| Baricitinib | 18.9 | 0.62 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
C199A | carcinoma_breast | Breast | https://www.cancer.gov/tcga. |
C199A | carcinoma_pancreas | Pancreas | https://www.cancer.gov/tcga. |